Novel Reversal Agents to Safely and Effectively Treat Direct Oral Anticoagulant Bleeding: Education for the Health-System Pharmacist

Novel Reversal Agents to Safely and Effectively Treat Direct Oral Anticoagulant Bleeding: Education for the Health-System Pharmacist

On-Demand 1-hour Accredited Webcast

Faculty Presenter

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts
 
Program Description
The availability of direct oral anticoagulants (DOACs) has improved outcomes for patients with atrial fibrillation or at risk of other thrombotic complications. Concerns remain when using DOACs due to lack of specific antidotes to reverse anticoagulation effects in the setting of emergent bleeding risk or when patients require surgery. Health-system pharmacists must be familiar with current reversal management guidelines to accurately evaluate patients who present with life-threatening bleeding events and identify timing of last dose of DOAC and its rate of elimination should a reversal agent be unavailable. Health-system pharmacists can lead efforts to develop specific protocols for use of DOAC reversal agents within their institutions and can organize training for hospital staff regarding preparation, administration, and dosing of these agents. System-level approaches to reversal of DOAC-related bleeding events can reduce delays in administration of reversal agents, thereby controlling bleeds sooner and improving outcomes for patients. Clinical data for agents under investigation for DOAC reversal, as well as real-world data for FDA-approved reversal agents, will be examined and should be considered when developing protocols and procedures.


Target Audience: Health-system pharmacist and managed care pharmacist
Type of Activity: Application
Release date: June 15, 2021
Expiration date: June 15, 2022
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Apply the most recent evidence-based guidelines to the selection of direct oral anticoagulant (DOAC) reversal agents in reversal of major bleeding associated with the use of DOACs.
   
• Explain the mechanisms of action, safety and efficacy, and adverse effects associated with the use of FDA-approved DOAC reversal agents
   
• Analyze clinical data and real-world evidence comparing the safety benefits of specific reversal agents over prothrombin complex concentrates for reversing life-threatening DOAC-related bleeding
   
• Identify the role of the health-system pharmacist in improving patient outcomes with clinical recommendations regarding the proper use of DOAC reversal agents, anticoagulation monitoring protocols, and successful transitions of care of patients after a bleeding event

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-245-H01-P. The activity is available for CE credit through June 15, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC, has the following relevant financial relationships with commercial interests to disclose:

Speaker’s Bureau: Janssen Pharmaceuticals, Inc. and Portola Pharmaceuticals

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liz Rauh; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms